We are pleased to share this SuperCrowd Voices from the Community post with you. SuperCrowd Voices posts represent the views of our guest authors, not The Super Crowd, Inc., a public benefit corporation. Manage the volume of emails you receive from us by clicking here. Interested in sharing your voice? Click here.
Despite staggering investments in Cancer treatments, most patients still face limited benefits—especially when diagnosed late. Jonathan Cohen, founder and CEO of 20/20 Biolabs, believes that the true key to saving lives lies not in better treatments, but in earlier detection.
“I saw massive funding of and spending by biotech companies in developing treatments, but very little going to companies focused on early disease detection and prevention, which can be far more impactful,” Cohen says. “Unlike with infectious disease, the effectiveness of treatments for cancer and most chronic diseases is quite limited. Even the latest approved cancer drugs typically extend the lives of those with metastatic disease by only a few weeks or 2-3 months at best.”
By contrast, prevention—particularly early detection—offers a much better return on investment, not only in dollars but in lives saved. Through 20/20 Biolabs, Cohen has launched a line of AI-powered blood tests designed to do just that.
Under the OneTest brand, Cohen’s team has developed two main products: OneTest for Cancer, a multi-cancer early detection (MCED) blood test, and OneTest for Longevity, which measures inflammatory biomarkers. The second product is expected to launch in October.
“Our multi-cancer early detection blood test helps detect cancers at earlier stages when they can most effectively be treated,” Cohen explains. “Over 20,000 tests have been purchased to date, and many have already benefitted from our test.”
What makes OneTest stand out is its accessibility. “We offer the only multi-cancer early detection blood test in the U.S. market that is available for under $250, can be collected at home, and which has good sensitivity for earlier stage cancers,” he says.
That’s a stark contrast to competitors. “Our main competitor—the Galleri test from Grail—costs just under $1,000, requires a phlebotomy blood draw, and misses most early-stage cancers according to Grail’s own published data.”
The company has found a key audience in a high-risk population: firefighters. “Firefighters—who have proven high incidence and deaths from various cancers—have been a major part of our customer base, with over 250 fire departments using our MCED.”
While the science is compelling, Cohen is equally focused on scaling the business. “We are taking concrete steps to become a Nasdaq listed company before the end of this year,” he says. “That includes filing a draft Registration Statement, engaging an investment banking firm with significant experience in direct listings, and submitting a listing application with Nasdaq.”
The vision doesn’t stop with an IPO. “This status, coupled with some large investments, will enable us to not only scale our current product line but to ‘roll-up’ several related companies through M&A,” Cohen explains. “These include companies that are vertically integrated with us—suppliers and marketing channels—as well as companies with complementary products we can offer our consumers.”
That strategy offers both vertical and horizontal Growth, aimed at building a healthtech powerhouse with wide-ranging capabilities.
Unlike many biotech startups that focus heavily on research and proprietary science, 20/20 Biolabs has taken a more pragmatic route—one grounded in solving real problems with proven tools.
“Focus on solving a big problem rather than a technical solution,” Cohen advises other founders. “This is a very common mistake with biotech start-ups in particular. Companies with scientific founders too often fall in Love with their Technology and can be blinded to alternative approaches that might perform equally well with far less developmental costs and timelines.”
To that end, 20/20 Biolabs’ cancer detection tests measure widely accepted biomarkers such as CEA and CA 19.9—well-known in the medical community. What sets the company apart is not inventing new biomarkers, but applying machine learning to interpret results more powerfully, and distributing the test in a convenient, affordable format.
“Development of our multi-cancer test… leveraged real-world data from parts of the world where such testing is commonplace,” Cohen says. “Thus, we invested far less than 1% of the billions of dollars funds spent by Grail, and many of our consumers and industry Experts believe we have a superior test.”
In the crowded world of regulated investment Crowdfunding, few offerings stand out like 20/20 Biolabs’. For investors, the company is offering a rare feature: a convertible debt round with a built-in liquidity path.
“We are offering a convertible debt round that automatically converts to equity upon listing on Nasdaq at a 20% discount,” Cohen explains. “If we fail to go public within 24 months, the investor gets their Money back with 15% interest.”
That’s a striking offer, particularly in a crowdfunding environment where investors often wait years—and sometimes forever—for an exit.
“Such an opportunity for near-term profits is likely unprecedented among crowdfunding companies, 98% of which have failed to give their shareholders a path to liquidity despite more than 10 years since equity crowdfunding went online,” he says.
For impact investors seeking both financial return and social benefit, the offering provides an enticing mix: a real shot at liquidity combined with the chance to support life-saving Innovation.
Jonathan Cohen brings a unique mix of legal, scientific, and business experience to the venture. A registered patent attorney with over 25 years in biotech intellectual property, Cohen previously served as general counsel for two publicly traded companies—Ventana Medical Systems (acquired by Roche) and Oncor Inc. He also holds a Master of Science in Biotechnology from Johns Hopkins and a law degree from American University.
As CEO of 20/20 Biolabs, Cohen co-invented both OneTest and another product, BioCheck, and has led deals with companies like Johnson & Johnson, IBM, and Abbott Diagnostics.
He’s not just an innovator—he’s an advocate. Cohen has been active in lobbying for small biotech and diagnostics companies at both the state and federal levels, championing policies to support emerging science-based ventures.
With its upcoming launch of a longevity test, plans for a Nasdaq listing, and a compelling investment structure, 20/20 Biolabs stands at a pivotal moment.
For Cohen, the mission remains simple: save more lives, earlier, and for less money.
That’s the kind of vision that speaks not only to patients and families—but also to a new generation of impact-minded investors ready to change the world, one smart bet at a time.
Mr. Cohen is the founder of 20/20 Biolabs and has served as Chief Executive Officer, President, and a director since its inception. He is a co-inventor of two of our most successful products, OneTest and BioCheck, and has led the commercial launch and sales of both. He has also spearheaded license, research, technology transfer, investment, and sales and marketing agreements with Fortune 500 companies such as Eastman Kodak, Abbott Diagnostics, Johnson & Johnson, IBM, and Ping An, the largest Health insurance company in China. Mr. Cohen has also been a leading advocate in Annapolis, MD and on Capitol Hill on behalf of small and emerging biotechnology and diagnostics companies. Before founding our company, Mr. Cohen was patent and general counsel for two publicly traded companies, Ventana Medical Systems Inc. (acquired by Roche diagnostics in 2008), from 1999 to 2000, and Oncor Inc., from 1997 to 1999. Mr. Cohen is a registered patent attorney with more than 25 years of experience in biotechnology patents and licensing matters. Mr. Cohen has a Master of Science Degree in Biotechnology from Johns Hopkins University and a law degree from the American University. We believe that Mr. Cohen is qualified to serve on our board of directors due to his experience in our industry and knowledge of our company.
Campaign Details:
20/20 Biolabs is raising funds via PicMii. The campaign closes August 8. To learn more, visit: picmiicrowdfunding.com.
The following Max-Impact Members provide valuable financial support:
Carol Fineagan, Independent Consultant | Hiten Sonpal, RISE Robotics | Lory Moore, Lory Moore Law | Marcia Brinton, High Desert Gear | Mark Grimes, Networked Enterprise Development | Matthew Mead, Hempitecture | Michael Pratt, Qnetic | Dr. Nicole Paulk, Siren Biotechnology | Paul Lovejoy, Stakeholder Enterprise | Pearl Wright, Global Changemaker | Ralf Mandt, Next Pitch | Scott Thorpe, Philanthropist | Sharon Samjitsingh, Health Care Originals | Add Your Name Here
If a location is not noted, the events below are virtual.
Impact Cherub Club Meeting hosted by The Super Crowd, Inc., a public benefit corporation, on August 19, 2025, at 1:30 PM Eastern. Each month, the Club meets to review new offerings for investment consideration and to conduct due diligence on previously screened deals. To join the Impact Cherub Club, become an Impact Member of the SuperCrowd.
SuperCrowdHour, August 20, 2025, at 12:00 PM Eastern. Devin Thorpe, CEO and Founder of The Super Crowd, Inc., will lead a session on “Your Portal, Your Future: How to Choose the Right Reg CF Platform.” With so many investment crowdfunding portals available today, selecting the right one can be overwhelming for both founders and investors. In this session, Devin will break down the critical factors to consider—such as platform fees, audience demographics, compliance support, industry focus, and overall user experience. Whether you’re a founder planning a raise or an investor exploring where to put your dollars to work, you’ll walk away with a clearer understanding of how to evaluate and choose the platform that best aligns with your goals. Don’t miss this practical, insight-packed hour designed to help you take your next step in the Reg CF ecosystem with confidence.
SuperCrowd25, August 21st and 22nd: This two-day virtual event is an annual tradition, but with big upgrades for 2025! We’ll be Streaming live across the web and on TV via e360tv. VIPs get access to our better-than-in-person networking, including backstage passes, VIP networking and an exclusive VIP webinar! Get your VIP access for just $25. A select group of affordable sponsorship opportunities is still available. Learn more here.
Successful Funding with Karl Dakin, Tuesdays at 10:00 AM ET – Click on Events.
Devin Thorpe is featured in a free virtual masterclass series hosted by Irina Portnova titled Break Free, Elevate Your Money Mindset & Call In Overflow, focused on transforming your relationship with money through personal stories and practical insights. June 8-21, 2025.
Join Dorian Dickinson, founder & CEO of FundingHope, for Startup.com’s monthly crowdfunding workshop, where he’ll dive into strategies for successfully raising capital through investment crowdfunding. June 24 at noon Eastern.
Future Forward Summit: San Francisco, Wednesday, June 25 · 3:30 – 8:30 pm PDT.
Regulated Investment Crowdfunding Summit 2025, Crowdfunding Professional Association, Washington DC, October 21-22, 2025.
Impact Accelerator Summit is a live, in-person event taking place in Austin, Texas, from October 23–25, 2025. This exclusive gathering brings together 100 heart-centered, conscious entrepreneurs generating $1M+ in revenue with 20–30 Family offices and venture funds actively seeking to invest in world-changing businesses. Referred by Michael Dash, participants can expect an inspiring, high-impact experience focused on capital connection, growth, and global impact.
If you would like to submit an event for us to share with the 9,000+ changemakers, investors and entrepreneurs who are members of the SuperCrowd, click here.
Manage the volume of emails you receive from us by clicking here.
Originally Published on https://www.superpowers4good.com/
